NO940180L - Anvendelse av IGF-I - Google Patents

Anvendelse av IGF-I

Info

Publication number
NO940180L
NO940180L NO940180A NO940180A NO940180L NO 940180 L NO940180 L NO 940180L NO 940180 A NO940180 A NO 940180A NO 940180 A NO940180 A NO 940180A NO 940180 L NO940180 L NO 940180L
Authority
NO
Norway
Prior art keywords
igf
treatment
type
diabetes mellitus
drug
Prior art date
Application number
NO940180A
Other languages
English (en)
Norwegian (no)
Other versions
NO940180D0 (no
Inventor
David B Dunger
Martin O Savage
Peter H Soenksen
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO940180D0 publication Critical patent/NO940180D0/no
Publication of NO940180L publication Critical patent/NO940180L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO940180A 1992-05-19 1994-01-18 Anvendelse av IGF-I NO940180L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1
PCT/SE1993/000425 WO1993023071A1 (en) 1992-05-19 1993-05-14 Use of igf-1

Publications (2)

Publication Number Publication Date
NO940180D0 NO940180D0 (no) 1994-01-18
NO940180L true NO940180L (no) 1994-01-18

Family

ID=20386281

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940180A NO940180L (no) 1992-05-19 1994-01-18 Anvendelse av IGF-I

Country Status (11)

Country Link
US (1) US5466670A (de)
EP (1) EP0613376B1 (de)
JP (1) JPH06509361A (de)
AT (1) ATE207758T1 (de)
AU (1) AU669894B2 (de)
CA (1) CA2112358A1 (de)
DE (1) DE69331045T2 (de)
NO (1) NO940180L (de)
NZ (1) NZ252359A (de)
SE (1) SE9201573D0 (de)
WO (1) WO1993023071A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
US20060088575A1 (en) * 1994-03-31 2006-04-27 Brewitt Barbara A Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
RU2165767C1 (ru) * 2000-06-09 2001-04-27 Чернов Юрий Николаевич Антидиабетическое средство
JP2004518647A (ja) 2000-12-15 2004-06-24 ナチュラルエンド テック カンパニー リミテッド インシュリン様成長因子−１の分泌誘導用薬剤学的組成物および食品組成物
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
WO2002072780A2 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
JP2008511838A (ja) 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
WO2013050529A2 (en) * 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) * 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
NZ252359A (en) 1997-05-26
US5466670A (en) 1995-11-14
AU4098893A (en) 1993-12-13
NO940180D0 (no) 1994-01-18
JPH06509361A (ja) 1994-10-20
EP0613376B1 (de) 2001-10-31
CA2112358A1 (en) 1993-11-25
AU669894B2 (en) 1996-06-27
DE69331045D1 (de) 2001-12-06
ATE207758T1 (de) 2001-11-15
DE69331045T2 (de) 2002-03-21
SE9201573D0 (sv) 1992-05-19
EP0613376A1 (de) 1994-09-07
WO1993023071A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
NO940180L (no) Anvendelse av IGF-I
MX9701916A (es) Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie.
TR200100079T2 (tr) Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
ATE82507T1 (de) Medizinische verwendung.
IT8323559A0 (it) Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
MD1558G2 (ro) Metoda de profilaxie a insuficientei renale acute la mamifere cu aplicarea factorului de creştere de tip insulinic IGF-I
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
DE69226835D1 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
ES8507567A1 (es) Metodo para estabilizar un concentrado de gamma globulina
GB8805792D0 (en) Medicaments
EP0700681A4 (de) Nährtransfusionslösung zur verabreichung in eine periphere vene
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
DE3787185D1 (de) Methode zur Erhöhung des Wachstums des Brustzellgewebes.
DK0914148T3 (da) Behandling af partielt væksthormonoverfølsomhedssyndrom
DK35588A (da) Hoejniveau-ekspression i e. coli af oploeseligt, modent humant interleukin-1beta og derivater med aendret biologisk virkning
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
CA2405265A1 (en) Method of preventing or treating diabetes
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
Gemsenjäger et al. Contralateral Papillary Thyroid Cancer—High Incidence in Therapeutic Completion Thyroidectomy
Schlüter et al. Therapeutic efficiency of biosynthetic human insulin in patients with newly diagnose type I diabetes mellitus.
Holst et al. Diurnal profile of pancreatic polypeptide and gut glucagon in human morbid obesity
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen